Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by complex lung pathogenesis affecting approximately three million people worldwide. While the molecular and cellular details of the IPF mechanism is emerging, our current understanding is centered around the lung itself. On the other hand, many human diseases are the products of complex multi-organ interactions. Hence, we postulate that a dysfunctional crosstalk of the lung with other organs plays a causative role in the onset, progression and/or complications of IPF. In this study, we employed a generative computational approach to identify such inter-organ mechanism of IPF. This approach found unexpected molecular relatedness of IPF to neoplasm, diabetes, Alzheimer’s disease, obesity, atherosclerosis, and arteriosclerosis. Furthermore, as a potential mechanism underlying this relatedness, we uncovered a putative molecular crosstalk system across the lung and the liver. In this inter-organ system, a secreted protein, kininogen 1, from hepatocytes in the liver interacts with its receptor, bradykinin receptor B1 in the lung. This ligand–receptor interaction across the liver and the lung leads to the activation of calmodulin pathways in the lung, leading to the activation of interleukin 6 and phosphoenolpyruvate carboxykinase 1 pathway across these organs. Importantly, we retrospectively identified several pre-clinical and clinical evidence supporting this inter-organ mechanism of IPF. In conclusion, such feedforward and feedback loop system across the lung and the liver provides a unique opportunity for the development of the treatment and/or diagnosis of IPF. Furthermore, the result illustrates a generative computational framework for machine-mediated synthesis of mechanisms that facilitates and complements the traditional experimental approaches in biomedical sciences.

Details

Title
Latent inter-organ mechanism of idiopathic pulmonary fibrosis unveiled by a generative computational approach
Author
Kozawa, Satoshi 1 ; Tejima, Kengo 2 ; Takagi, Shunki 2 ; Kuroda, Masataka 3 ; Nogami-Itoh, Mari 4 ; Kitamura, Hideya 5 ; Niwa, Takashi 5 ; Ogura, Takashi 5 ; Natsume-Kitatani, Yayoi 6 ; Sato, Thomas N. 7 

 Karydo TherapeutiX, Inc., Kyoto, Japan; Advanced Telecommunications Research Institute International (ATR), The Thomas N. Sato BioMEC-X Laboratories, Kyoto, Japan (GRID:grid.418163.9) (ISNI:0000 0001 2291 1583) 
 Karydo TherapeutiX, Inc., Kyoto, Japan (GRID:grid.418163.9); Advanced Telecommunications Research Institute International (ATR), The Thomas N. Sato BioMEC-X Laboratories, Kyoto, Japan (GRID:grid.418163.9) (ISNI:0000 0001 2291 1583) 
 National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (GRID:grid.482562.f); Mitsubishi Tanabe Pharma Corporation, Kanagawa, Japan (GRID:grid.482562.f) (ISNI:0000 0004 0629 2251) 
 National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (GRID:grid.482562.f) 
 Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan (GRID:grid.419708.3) (ISNI:0000 0004 1775 0430) 
 National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (GRID:grid.482562.f); Tokushima University, Institute of Advanced Medical Sciences, Tokushima, Japan (GRID:grid.267335.6) (ISNI:0000 0001 1092 3579) 
 Karydo TherapeutiX, Inc., Kyoto, Japan (GRID:grid.267335.6); Advanced Telecommunications Research Institute International (ATR), The Thomas N. Sato BioMEC-X Laboratories, Kyoto, Japan (GRID:grid.418163.9) (ISNI:0000 0001 2291 1583); Nara Medical University, V-iCliniX Laboratory, Nara, Japan (GRID:grid.410814.8) (ISNI:0000 0004 0372 782X) 
Pages
21981
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2900474613
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.